Conflict of Interest, Round 2

Freedman, Robert; Lewis, David A.; Michels, Robert; Pine, Daniel S.; Schultz, Susan K.; Tamminga, Carol A.; Patterson, Sandra L.; McIntyre, John S.; Goldman, Howard H.; Yudofsky, Stuart C.; Hales, Robert E.; Rapaport, Mark Hyman; Hales, Deborah J.; Krajeski, James P.; Kupfer, David J.; Badaracco, Mary Anne; Scully, James H.

doi:10.1176/ajp.2006.163.9.1481

Cited by 7 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recognition of this fact has recently led to what is regularly called "a crisis in the perceived integrity of all clinical trials", notably those involving the SSRIs [4,[75][76][77][78]. In contrast with the rest of medicine, however, only belatedly has the extent of the crisis begun to be publicly acknowledged in psychiatric journals [35,79].…”

Section: Adverse Drug Reactions: Understudied Under-recognized Undementioning

confidence: 99%

Randomized controlled trials of antidepressants: clinically and scientifically irrelevant

Cohen

Jacobs²

2007

Debates in Neuroscience

View full text Add to dashboard Cite

This contribution to the "antidepressant debate" focuses on the validity of randomized controlled trials (RCTs). We argue that: (a) made-up psychiatric diagnostic categories destroy the purpose and logic of the RCT as a medical experiment, (b) RCTs do everything possible to methodologically stamp out high placebo response rates rather than reveal their clinical implications, (c) assessing a psychoactive drug's effects greatly exceeds the RCT's purpose, requiring substantial investigation on normal volunteers, and (d) adverse drug reactions remain understudied, under-recognized, and underappreciated, in parallel with the muting of subjects' voice and the reliance on surrogate measures of efficacy. The standard psychopharmacotherapy RCT has lost virtually all clinical and scientific relevance, and needs complete revamping. The backdrop for the discussion is American biopsychiatry's insistence that personal difficulties must be viewed as the expression of idiopathic somatic diseases and the pharmaceutical industry's dominance of the entire drug treatment research enterprise.

show abstract

Section: Adverse Drug Reactions: Understudied Under-recognized Undementioning

confidence: 99%

Randomized controlled trials of antidepressants: clinically and scientifically irrelevant

Cohen

Jacobs²

2007

Debates in Neuroscience

View full text Add to dashboard Cite

show abstract

“…The position that a complete separation between industry and academic research, and of course even more obviously a disinvestment in psychopharmacological research, would be highly detrimental to our field has been outlined (Freedman et al, 2006). Despite this, industry funding of psychopharmacologic treatments seems to have declined in general and perhaps even more so in pediatric mental health as a result of this issue.…”

mentioning

confidence: 99%

Research in Pediatric Psychopharmacology: Pushing the Pendulum Back to the Midline

Luby¹

2014

Child and Adolescent Psychopharmacology News

View full text Add to dashboard Cite

Collaborations between academic psychiatry and the pharmaceutical industry: A perspective from industry

Tohen¹

2007

Epidemiol Psichiatr Soc

View full text Add to dashboard Cite

show abstract

Conflict of Interest, Round 2

Cited by 7 publications

References 6 publications

Randomized controlled trials of antidepressants: clinically and scientifically irrelevant

Randomized controlled trials of antidepressants: clinically and scientifically irrelevant

Research in Pediatric Psychopharmacology: Pushing the Pendulum Back to the Midline

Collaborations between academic psychiatry and the pharmaceutical industry: A perspective from industry

Contact Info

Product

Resources

About